Combined versus traditional photocoagulation treatment for aggressive posterior retinopathy of prematurity (APROP)
Reviewed by Fiona Rowe

The purpose was to report the outcomes of the combined treatment of sparing laser photocoagulation and intravitreal Bevacizumab (IVB) treatment versus conventional laser photocoagulation intervention in APROP. This was a study of 18 eyes of nine infants. One was excluded with loss to follow-up, leaving 16 eyes of eight infants. Eight eyes (four infants) underwent combined treatment, and eight eyes (eight infants) underwent conventional treatment. ROP regressed with satisfactory anatomical outcome in all eyes of combined treatment and in six of eight eyes in conventional treatment (two eyes developed partial retinal detachment). Two eyes in the combined treatment group developed recurrent stage ROP and had further laser photocoagulation. The average time to total regression of ROP was 56 days in the conventional group and 34 days in the combined group. Laser spots were significantly less in the combined treatment. There were no serious adverse events although the authors acknowledge the small sample size and thus the need for further large multicentre trials with longer follow-up.

Comparison of outcomes between combined sparing laser photocoagulation and intravitreal Bevacizumab treatment versus conventional laser photocoagulation in aggressive posterior ROP.
Ittarat M.
JOURNAL OF PEDIATRIC OPHTHALMOLOGY AND STRABISMUS
2021;58:292-7.